Table 2.
Patient Clinical Characteristics at Time of SCT
| Characteristic | Primary Diagnosis at Time of SCT |
P | |||
|---|---|---|---|---|---|
| CLL |
RT |
||||
| No. | % | No. | % | ||
| Total No. of patients | 52 | 72 | 20 | 28 | |
| Age at time of transplantation, years | .94 | ||||
| Median | 58 | 58 | |||
| Range | 30-72 | 32-72 | |||
| < 50 | 6 | 11 | 4 | 20 | |
| ≥ 50 to < 65 | 39 | 75 | 11 | 55 | |
| ≥ 65 | 7 | 14 | 5 | 25 | |
| ECOG performance status | |||||
| 0 | 4 | 20 | 16 | 31 | .59 |
| 1 | 13 | 65 | 31 | 60 | |
| 2 or more | 3 | 15 | 5 | 9 | |
| No. of prior treatments | |||||
| 1 | 9 | 17 | 1 | 5 | .30 |
| 2 | 16 | 31 | 9 | 45 | |
| 3 or more | 27 | 52 | 10 | 50 | |
| Response to last treatment | |||||
| CR | 3 | 6 | 0 | .48 | |
| PR | 21 | 43 | 8 | 40 | |
| Refractory | 25 | 51 | 12 | 60 | |
| Time from diagnosis of CLL to SCT, months | .43 | ||||
| Median | 70 | 45 | |||
| Range | 11-167 | 12-161 | |||
| Bone marrow cellularity | .9 | ||||
| Percent | 50 | 45 | |||
| Range | 15-100 | 20-95 | |||
| Fludarabine refractory | 13 | 26 | 6 | 32 | .7 |
Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response; ECOG, Eastern Cooperative Oncology Group; PR, partial response; RT, Richter's transformation; SCT, stem-cell transplantation.